Is GT Biopharma Stock a Good Investment?
GT Biopharma Investment Advice | GTBP |
- Examine GT Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GT Biopharma's leadership team and their track record. Good management can help GT Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact GT Biopharma's business and its evolving consumer preferences.
- Compare GT Biopharma's performance and market position to its competitors. Analyze how GT Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if GT Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GT Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GT Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GT Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine GT Biopharma Stock
Researching GT Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company shares are held by company insiders. The book value of GT Biopharma was currently reported as 5.41. The company recorded a loss per share of 7.39. GT Biopharma last dividend was issued on the 21st of August 2017. The entity had 1:30 split on the 5th of February 2024.
To determine if GT Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GT Biopharma's research are outlined below:
| GT Biopharma appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewswire |
GT Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in GT Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to GT Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
GT Biopharma Target Price Consensus
GTBP target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. GT Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most GTBP analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand GTBP stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of GT Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGT Biopharma Target Price Projection
GT Biopharma's current and average target prices are 2.79 and 5.00, respectively. The current price of GT Biopharma is the price at which GT Biopharma is currently trading. On the other hand, GT Biopharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
GT Biopharma Market Quote on 3rd of December 2024
Target Price
Analyst Consensus On GT Biopharma Target Price
GT Biopharma Analyst Ratings
GT Biopharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about GT Biopharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of GT Biopharma's financials, market performance, and future outlook by experienced professionals. GT Biopharma's historical ratings below, therefore, can serve as a valuable tool for investors.Know GT Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GT Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GT Biopharma backward and forwards among themselves. GT Biopharma's institutional investor refers to the entity that pools money to purchase GT Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 27.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 12.0 | Blue Bell Private Wealth Management, Llc | 2024-09-30 | 10.0 | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 6.0 | Royal Bank Of Canada | 2024-09-30 | 5.0 | Jpmorgan Chase & Co | 2024-09-30 | 1.0 | Front Row Advisors Llc | 2024-09-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Dekabank Deutsche Girozentrale | 2024-06-30 | 978.4 K | Bank Of Montreal | 2024-09-30 | 29.9 K | Bmo Capital Markets Corp. | 2024-09-30 | 29.9 K |
GT Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.39 M.Market Cap |
|
GT Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.57) | |
| Return On Capital Employed | (1.82) | (1.91) | |
| Return On Assets | (0.54) | (0.51) | |
| Return On Equity | (1.02) | (1.07) |
Determining GT Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if GT Biopharma is a good buy. For example, gross profit margin measures GT Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GT Biopharma's profitability and make more informed investment decisions.
Evaluate GT Biopharma's management efficiency
GT Biopharma has return on total asset (ROA) of (0.6059) % which means that it has lost $0.6059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3148) %, meaning that it created substantial loss on money invested by shareholders. GT Biopharma's management efficiency ratios could be used to measure how well GT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/03/2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -1.91. At this time, GT Biopharma's Total Current Liabilities is relatively stable compared to the past year. As of 12/03/2024, Change To Liabilities is likely to grow to about 8.5 M, while Liabilities And Stockholders Equity is likely to drop slightly above 13.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.55 | 5.27 | |
| Tangible Book Value Per Share | 5.55 | 5.27 | |
| Enterprise Value Over EBITDA | 1.79 | 1.70 | |
| Price Book Value Ratio | 1.38 | 1.31 | |
| Enterprise Value Multiple | 1.79 | 1.70 | |
| Price Fair Value | 1.38 | 1.31 | |
| Enterprise Value | 20.5 M | 19.4 M |
GT Biopharma's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.57 |
Basic technical analysis of GTBP Stock
As of the 3rd of December, GT Biopharma owns the Standard Deviation of 4.74, market risk adjusted performance of 0.771, and Semi Deviation of 4.16. GT Biopharma technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.GT Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GT Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on GT Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GT Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
GT Biopharma's Outstanding Corporate Bonds
GT Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GT Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GTBP bonds can be classified according to their maturity, which is the date when GT Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| Garda World Security Corp BondUS36257BAA70 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand GT Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GT Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0863 | |||
| Market Risk Adjusted Performance | 0.771 | |||
| Mean Deviation | 3.62 | |||
| Semi Deviation | 4.16 | |||
| Downside Deviation | 4.52 | |||
| Coefficient Of Variation | 980.7 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.51 | |||
| Information Ratio | 0.0758 | |||
| Jensen Alpha | 0.4026 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0796 | |||
| Treynor Ratio | 0.761 | |||
| Maximum Drawdown | 27.96 | |||
| Value At Risk | (5.64) | |||
| Potential Upside | 8.53 | |||
| Downside Variance | 20.4 | |||
| Semi Variance | 17.27 | |||
| Expected Short fall | (4.00) | |||
| Skewness | 0.4357 | |||
| Kurtosis | 1.32 |
| Risk Adjusted Performance | 0.0863 | |||
| Market Risk Adjusted Performance | 0.771 | |||
| Mean Deviation | 3.62 | |||
| Semi Deviation | 4.16 | |||
| Downside Deviation | 4.52 | |||
| Coefficient Of Variation | 980.7 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.51 | |||
| Information Ratio | 0.0758 | |||
| Jensen Alpha | 0.4026 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0796 | |||
| Treynor Ratio | 0.761 | |||
| Maximum Drawdown | 27.96 | |||
| Value At Risk | (5.64) | |||
| Potential Upside | 8.53 | |||
| Downside Variance | 20.4 | |||
| Semi Variance | 17.27 | |||
| Expected Short fall | (4.00) | |||
| Skewness | 0.4357 | |||
| Kurtosis | 1.32 |
Consider GT Biopharma's intraday indicators
GT Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GT Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GT Biopharma Corporate Filings
8K | 27th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 21st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of October 2024 Other Reports | ViewVerify |
GTBP Stock media impact
Far too much social signal, news, headlines, and media speculation about GT Biopharma that are available to investors today. That information is available publicly through GTBP media outlets and privately through word of mouth or via GTBP internal channels. However, regardless of the origin, that massive amount of GTBP data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GT Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GT Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GT Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GT Biopharma alpha.
GT Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards GT Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
GT Biopharma Corporate Management
| Michael Breen | Interim Chairman | Profile | |
| Manu Ohri | Chief Officer | Profile | |
| Jeffrey MD | Consulting Advisor | Profile | |
| Gregory MD | Chief RD | Profile | |
| MPH MBA | VP Management | Profile | |
| PharmD MBA | Chief Officer | Profile | |
| Alan CPA | Chief Officer | Profile |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.